Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 101–200 of 1,020
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
“overexpression of MDR1), prediction of disease progression and likelihood of relapse [1, 2].”
α-Ketoglutarate links p53 to cell fate during tumour suppression
Morris, J. P., Yashinskie, J. J., Koche, R., Chandwani, R., Tian, S., Chen, C.-C., Baslan, T., Marinkovic, Z. S., Sánchez-Rivera, F. J., Leach, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1577-5 · Cited by 296
Neuzillet, C., Tijeras‐Raballand, A., Ragulan, C., Cros, J., Patil, Y., Martinet, M., Erkan, M., Kleeff, J., Wilson, J., Apte, M., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5224 · Cited by 295
“The International Cancer Genome Consortium (ICGC) dataset from Bailey et al [12], comprising 96 pancreatic samples (RNAseq), was used to assign pCAFassigner subtypes using PAM centroids generated from CAF primary cultures.”
BackgroundMethodInfluentialMelisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0246-z · Cited by 294
The Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 293
“In humans, T cell exclusion in PDA – with marked surrounding desmoplasia – is also well-described; however, a subset of primary pancreatic tumors do exhibit moderate infiltration of CD8+ T cells and other immune cells (Bailey et al., 2016; Balachandran et al., 2017; Fukunaga et al., 2004; Ino et al., 2013b; Wormann et…”
BackgroundCui Zhou, D., Jayasinghe, R. G., Chen, S., Herndon, J. M., Iglesia, M. D., Navale, P., Wendl, M. C., Caravan, W., Sato, K., Storrs, E., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01157-1 · Cited by 284
Nerve Dependence: From Regeneration to Cancer
Boilly, B., Faulkner, S., Jobling, P., & Hondermarck, H. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.005 · Cited by 290
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L., Kalimuthu, S. N., Selander, I., McPherson, T., Wilson, G. W., Chan-Seng-Yue, M. A., Borozan, I., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 289
Self-citationWerba, G., Weissinger, D., Kawaler, E. A., Zhao, E., Kalfakakou, D., Dhara, S., Wang, L., Lim, H. B., Oh, G., Jing, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36296-4 · Cited by 283
“We also assessed the bulk RNA-derived sub-type classi fi cations of Collisson, Bailey and Puleo 26 – 28 .”
Wang, Y., Liang, Y., Xu, H., Zhang, X., Mao, T., Cui, J., Yao, J., Wang, Y., Jiao, F., Xiao, X., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00271-4 · Cited by 285
SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update)
Oscanoa, J., Sivapalan, L., Gadaleta, E., Dayem Ullah, A. Z., Lemoine, N. R., & Chelala, C. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa420 · Cited by 280
“Using the Reactome pathway analysis feature, we further identified enrichments for driver variants within several core PDAC signaling pathways (axon guidance, NOTCH signaling, RAS signaling) (19).”
MethodChemotherapy for pancreatic cancer
Springfeld, C., Jäger, D., Büchler, M. W., Strobel, O., Hackert, T., Palmer, D. H., & Neoptolemos, J. P. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.02.025 · Cited by 281
Qian, Z. R., Rubinson, D. A., Nowak, J. A., Morales-Oyarvide, V., Dunne, R. F., Kozak, M. M., Welch, M. W., Brais, L. K., Da Silva, A., Li, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3420 · Cited by 260
Self-citationYang, X., Lu, Y., Hang, J., Zhang, J., Zhang, T., Huo, Y., Liu, J., Lai, S., Luo, D., Wang, L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0111 · Cited by 277
“Finally, we analyzed the correlation between LDHA and functional genes HIF1A, S100A8, and S100A9 in patients with PDAC using The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases (36).”
MethodMechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
Self-citationMartinelli, P., Carrillo-de Santa Pau, E., Cox, T., Sainz, B., Dusetti, N., Greenhalf, W., Rinaldi, L., Costello, E., Ghaneh, P., Malats, N., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311256 · Cited by 269
“…EMT, basality and dissemination, supporting its role as a PDAC tumour suppressor, further strengthened by the genomic losses that we and others observed, and by the hypermethylation of GATA6 promoter described recently.52 Finally, we propose GATA6 as a valuable marker to guide patient treatment.”
Self-citationVennin, C., Mélénec, P., Rouet, R., Nobis, M., Cazet, A. S., Murphy, K. J., Herrmann, D., Reed, D. A., Lucas, M. C., Warren, S. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10968-6 · Cited by 268
Self-citationCastillo, J., Bernard, V., San Lucas, F. A., Allenson, K., Capello, M., Kim, D. U., Gascoyne, P., Mulu, F. C., Stephens, B. M., Huang, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx542 · Cited by 267
“An emerging body of literature demonstrates that comprehensive characterization of cancer genomes has both diagnostic and prognostic utility, and may provide insights into formulating individualized treatment strategies [1, 2].”
BackgroundSelf-citationUveal melanoma: Towards a molecular understanding
Smit, K. N., Jager, M. J., de Klein, A., & Kiliҫ, E. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100800 · Cited by 264
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
Lomberk, G., Blum, Y., Nicolle, R., Nair, A., Gaonkar, K. S., Marisa, L., Mathison, A., Sun, Z., Yan, H., Elarouci, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04383-6 · Cited by 261
Modeling tumor phenotypes in vitro with three-dimensional bioprinting
Langer, E. M., Allen-Petersen, B. L., King, S. M., Kendsersky, N. D., Turnidge, M. A., Kuziel, G. M., Riggers, R., Samatham, R., Amery, T. S., Jacques, S. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.090 · Cited by 256
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 250
Self-citationChao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 246
“To explore whether neutrophil infiltration is associated with certain PDA subtypes, we used GSVA to compare the enrichment of previously defined PDA subtype gene sets in TAN-high andTAN-medium/low tumors (35, 36, 41).”
BackgroundMethodResultInfluentialPishvaian, M. J., Bender, R. J., Halverson, D., Rahib, L., Hendifar, A. E., Mikhail, S., Chung, V., Picozzi, V. J., Sohal, D., Blais, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0531 · Cited by 245
“Frequencies were comparable with those from other published datasets (5, 6, 23).”
ResultThe Immune Microenvironment in Pancreatic Cancer
Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., Alashkar Alhamwe, B., von Strandmann, E., Slater, E. P., Bartsch, J. W., Bauer, C., & Lauth, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197307 · Cited by 244
Danilova, L., Ho, W. J., Zhu, Q., Vithayathil, T., De Jesus-Acosta, A., Azad, N. S., Laheru, D. A., Fertig, E. J., Anders, R., Jaffee, E. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0822 · Cited by 242
“Our results are consistent with a recent integrated genomic analysis of PDAC that identified the existence of an "immunogenic" disease subset (6), but their analysis did not stratify PDAC based on PD-L1 or CD8 alone.”
BackgroundResultInfluentialNRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Heining, C., Horak, P., Uhrig, S., Codo, P. L., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0036 · Cited by 240
Targeting Rac and Cdc42 GTPases in Cancer
Maldonado, M. D. M., & Dharmawardhane, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0619 · Cited by 237
Rashid, N. U., Peng, X. L., Jin, C., Moffitt, R. A., Volmar, K. E., Belt, B. A., Panni, R. Z., Nywening, T. M., Herrera, S. G., Moore, K. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1467 · Cited by 237
“A subsequent study of patients with pancreatic cancer, based onmore diverse pancreatic cancer histologies in addition to the most common pancreatic ductal adenocarcinoma (PDAC), found four molecular subtypes (4): Bailey (i) squamous, (ii) pancreatic progenitor, (iii) immunogenic, and (iv) aberrantly differentiated end…”
BackgroundMolecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Katoh, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3689 · Cited by 211
“…to ubiquitylation-mediated proteasomal degradation and induce the upregulation of oncogenic target genes, including CCND1 and MYC , in adrenocortical tumors, bladder cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer and uterine cancer (35 -40).”
Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V., McIntyre, C. A., El Dika, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 237
Self-citationMetabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Candido, J. B., Morton, J. P., Bailey, P., Campbell, A. D., Karim, S. A., Jamieson, T., Lapienyte, L., Gopinathan, A., Clark, W., McGhee, E. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.131 · Cited by 224
Self-citationImmune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 235
“Several recent studies have identified distinct genetic and transcriptional PDA tumor and stromal subtypes, which may present opportunities to identify individual patients likely to respond to targeted therapies (6-10).”
BackgroundInfluentialBiology and evolution of poorly differentiated neuroendocrine tumors
Rickman, D. S., Beltran, H., Demichelis, F., & Rubin, M. A. (2017) · Nature Medicine · doi:10.1038/nm.4341 · Cited by 231
Sack, L. M., Davoli, T., Li, M. Z., Li, Y., Xu, Q., Naxerova, K., Wooten, E. C., Bernardi, R. J., Martin, T. D., Chen, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.037 · Cited by 229
“NEUROD1 and NEUROD2 have been implicated in pancreas development and NEUROD1 was recently found overexpressed in PAAD (Bailey et al., 2016).”
BackgroundSelf-citationTargeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A., Chan-Seng-Yue, M., Wilson, G., Grant, R. C., Merico, D., Lungu, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.010 · Cited by 231
Self-citationTP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma
Somerville, T. D. D., Xu, Y., Miyabayashi, K., Tiriac, H., Cleary, C. R., Maia-Silva, D., Milazzo, J. P., Tuveson, D. A., & Vakoc, C. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.051 · Cited by 225
Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models
Thomas, R. M., Gharaibeh, R. Z., Gauthier, J., Beveridge, M., Pope, J. L., Guijarro, M. V., Yu, Q., He, Z., Ohland, C., Newsome, R., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy073 · Cited by 222
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Zhang, T., Ren, Y., Yang, P., Wang, J., & Zhou, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05351-1 · Cited by 214
“PDAC typically develops a dense fibrotic stroma with an abundance of extracellular matrix (ECM) due to the inflammation-induced desmoplastic reaction [7].”
BackgroundKocher, H. M., Basu, B., Froeling, F. E. M., Sarker, D., Slater, S., Carlin, D., deSouza, N. M., De Paepe, K. N., Goulart, M. R., Hughes, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18636-w · Cited by 217
Checkpoint inhibitors in pancreatic cancer
Henriksen, A., Dyhl-Polk, A., Chen, I., & Nielsen, D. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.005 · Cited by 216
Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes
Maurer, C., Holmstrom, S. R., He, J., Laise, P., Su, T., Ahmed, A., Hibshoosh, H., Chabot, J. A., Oberstein, P. E., Sepulveda, A. R., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317706 · Cited by 216
Drifka, C. R., Loeffler, A. G., Mathewson, K., Keikhosravi, A., Eickhoff, J. C., Liu, Y., Weber, S. M., Kao, W. J., & Eliceiri, K. W. (2016) · Oncotarget · doi:10.18632/oncotarget.12772 · Cited by 213
Modeling Pancreatic Cancer with Organoids
Baker, L. A., Tiriac, H., Clevers, H., & Tuveson, D. A. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.03.004 · Cited by 210
Lowery, M. A., Jordan, E. J., Basturk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., Leach, T., Herbst, B., Askan, G., Maynard, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0899 · Cited by 212
“The integration of RNA expression analysis with whole-genome sequencing has allowed alternative subclassification of pancreatic adenocarcinomas which provide rationale for several putative therapeutic strategies (8).”
BackgroundSelf-citationKarasinska, J. M., Topham, J. T., Kalloger, S. E., Jang, G. H., Denroche, R. E., Culibrk, L., Williamson, L. M., Wong, H.-L., Lee, M. K. C., O'Kane, G. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1543 · Cited by 211
“To determine oncogenic events across the different metabolic subtypes, we investigated the frequency of SNV, indels, and CNV affecting genes frequently mutated in PDAC (2, 6, 7) across the metabolic subtypes (Fig.”
BackgroundMethodResultInfluentialAn update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Van Laethem, J.-L., Malka, D., Ducreux, M., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 211
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Self-citationMelisi, D., Oh, D.-Y., Hollebecque, A., Calvo, E., Varghese, A., Borazanci, E., Macarulla, T., Merz, V., Zecchetto, C., Zhao, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002068 · Cited by 206
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207
“…mutations, gain-of-function CTNNB1 mutations or loss-of-function RNF43 or ZNRF3 mutations have also been reported in breast cancer (33), gastric cancer (34), hepatocellular carcinoma (35), lung cancer (36), pancreatic cancer (37), prostate cancer (38) and uterine corpus endometrial carcinoma (39).”
BackgroundImmune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Martinez-Bosch, N., Vinaixa, J., & Navarro, P. (2018) · Cancers · doi:10.3390/cancers10010006 · Cited by 209
“More recent studies from the Australian Pancreatic Cancer Genome Initiative/International Cancer Genome Consortium [27] and from The Cancer Genome Atlas (TCGA) network [28] have validated these results and have also added a long list of other less-frequently mutated genes, confirming the complex molecular landscape of…”
BackgroundHypermutation In Pancreatic Cancer
Humphris, J. L., Patch, A.-M., Nones, K., Bailey, P. J., Johns, A. L., McKay, S., Chang, D. K., Miller, D. K., Pajic, M., Kassahn, K. S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.060 · Cited by 209
“…0 1 2 2 N/A N/A N/A N/A N/A N/A N/A ICGC_0094 Exome Bailey et al 2016 other 222.53 15.50 0.200 0.00 0 0 N/A N/A N/A N/A N/A N/A N/A ICGC_0404 Exome Bailey et al 2016 other 98.15 18.45 0.180 0.01 0 0 N/A N/A N/A N/A N/A N/A N/A ICGC_0266 Exome Bailey et al 2016 other 104.54 17.67 0.160 0.01 0 0…”
InfluentialSelf-citationDNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Perkhofer, L., Gout, J., Roger, E., Kude de Almeida, F., Baptista Simões, C., Wiesmüller, L., Seufferlein, T., & Kleger, A. (2021) · Gut · doi:10.1136/gutjnl-2019-319984 · Cited by 206
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt-Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 203
Zhu, Z., Achreja, A., Meurs, N., Animasahun, O., Owen, S., Mittal, A., Parikh, P., Lo, T.-W., Franco-Barraza, J., Shi, J., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0226-5 · Cited by 204
Self-citationSharma, A., Smyrk, T. C., Levy, M. J., Topazian, M. A., & Chari, S. T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.025 · Cited by 204
LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9
Fu, Z., Chen, C., Zhou, Q., Wang, Y., Zhao, Y., Zhao, X., Li, W., Zheng, S., Ye, H., Wang, L., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.019 · Cited by 204
Hayashi, A., Fan, J., Chen, R., Ho, Y.-J., Makohon-Moore, A. P., Lecomte, N., Zhong, Y., Hong, J., Huang, J., Sakamoto, H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0010-1 · Cited by 203
Self-citationGabitova-Cornell, L., Surumbayeva, A., Peri, S., Franco-Barraza, J., Restifo, D., Weitz, N., Ogier, C., Goldman, A. R., Hartman, T. R., Francescone, R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.015 · Cited by 203
“Activation of the transforming growth factor beta (TGFβ) pathway a defining feature of basal PDAC, leading to increased expression of genes associated with a mesenchymal phenotype, including transcription factors ZEB1, ZEB2, TWIST, SNAI1, and SNAI2 (Scheel et al., 2011), as well as reduced expression of epithelial adh…”
BackgroundReshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 202
Self-citationT-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 197
“Still other studies suggest that T cells are the dominant immune cell in PDA (15, 26) and 25% of PDAs have been classified as an immunogenic subset, with higher expression of immune related genes based on genomic profiling (20).”
BackgroundResultNicolle, R., Blum, Y., Marisa, L., Loncle, C., Gayet, O., Moutardier, V., Turrini, O., Giovannini, M., Bian, B., Bigonnet, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.003 · Cited by 199
“…cancer ICGC (International Cancer Genome Consortium) project defined four subtypes of PDAC based on the transcriptomic analysis of 96 selected primary tumors (Bailey et al., 2016), which they named squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX).”
BackgroundMethodResultInfluentialOncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer
Humpton, T. J., Alagesan, B., DeNicola, G. M., Lu, D., Yordanov, G. N., Leonhardt, C. S., Yao, M. A., Alagesan, P., Zaatari, M. N., Park, Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1409 · Cited by 198
“Patients whose tumors were determined to be non-PDAC by histopathologic analysis were excluded (2).”
BackgroundWartenberg, M., Cibin, S., Zlobec, I., Vassella, E., Eppenberger-Castori, S., Terracciano, L., Eichmann, M. D., Worni, M., Gloor, B., Perren, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3401 · Cited by 197
“The expression pattern as well as the molecular and clinical characteristics of the immune-escape phenotype largely overlapwith the squamous subtypedescribedbyBailey and colleagues (16) or the quasi-mesenchymal subtype described by Collisson and colleagues (17), whereas the pattern that characterizes the immune-rich p…”
BackgroundMethodLiang, C., Shi, S., Qin, Y., Meng, Q., Hua, J., Hu, Q., Ji, S., Zhang, B., Xu, J., & Yu, X.-J. (2020) · Gut · doi:10.1136/gutjnl-2018-317163 · Cited by 198
Cell-free DNA analysis in current cancer clinical trials: a review
Cisneros-Villanueva, M., Hidalgo-Pérez, L., Rios-Romero, M., Cedro-Tanda, A., Ruiz-Villavicencio, C. A., Page, K., Hastings, R., Fernandez-Garcia, D., Allsopp, R., Fonseca-Montaño, M. A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01696-0 · Cited by 198
“These results suggest that the presence of G12V mutations in ctDNA has clinical utility as a prognostic tool and support the use of non-invasive techniques for the detection of mutations in patients with PDAC [69].”
BackgroundPancreatic cancer treatment: better, but a long way to go
Torphy, R. J., Fujiwara, Y., & Schulick, R. D. (2020) · Surgery Today · doi:10.1007/s00595-020-02028-0 · Cited by 197
Pettitt, S. J., Frankum, J. R., Punta, M., Lise, S., Alexander, J., Chen, Y., Yap, T. A., Haider, S., Tutt, A. N. J., & Lord, C. J. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1485 · Cited by 195
“…homologous recombination (HR) DNA repair, such as BRCA1, BRCA2, RAD51C, RAD51D and PALB2, are common in cancer and are enriched in high grade serous ovarian cancers (HGSOC (1)), triple-negative breast cancer (TNBC (2,3)) castrate resistant metastatic prostate cancer (4) and pancreatic cancer (5–7).”
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Pathology of pancreatic cancer
Haeberle, L., & Esposito, I. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.06.02 · Cited by 193
“Five years after that, Bailey and colleagues were able to determine four molecular subtypes of PDAC based on whole exome sequencing and copy number variation (CNV) analysis, which partially overlapped with Collisson’s subtypes (31).”
BackgroundKRAS drives immune evasion in a genetic model of pancreatic cancer
Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 191
Patra, K. C., Kato, Y., Mizukami, Y., Widholz, S., Boukhali, M., Revenco, I., Grossman, E. A., Ji, F., Sadreyev, R. I., Liss, A. S., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0122-3 · Cited by 192
Knudsen, E. S., Vail, P., Balaji, U., Ngo, H., Botros, I. W., Makarov, V., Riaz, N., Balachandran, V., Leach, S., Thompson, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0162 · Cited by 191
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip, P. A., Azar, I., Xiu, J., Hall, M. J., Hendifar, A. E., Lou, E., Hwang, J. J., Gong, J., Feldman, R., Ellis, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3581 · Cited by 191
Omori, Y., Ono, Y., Tanino, M., Karasaki, H., Yamaguchi, H., Furukawa, T., Enomoto, K., Ueda, J., Sumi, A., Katayama, J., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.10.029 · Cited by 190
“Figure 1A) and concomitant PDA as PDA without continuity with IPMN or that adjoining LG IPMN (Supplementary Figure 1B), based on the previously described criteria.(8,21)”
BackgroundMethodSurvival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Trovato, R., Fiore, A., Sartori, S., Canè, S., Giugno, R., Cascione, L., Paiella, S., Salvia, R., De Sanctis, F., Poffe, O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0734-6 · Cited by 189
“Only in the recent past, PDAC was deeply interrogated at the genetic level, therefore revealing the presence of different molecular subtypes and, among them, an immune subgroup [51].”
BackgroundSelf-citationGlutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer
Recouvreux, M. V., Moldenhauer, M. R., Galenkamp, K. M. O., Jung, M., James, B., Zhang, Y., Lowy, A., Bagchi, A., & Commisso, C. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200388 · Cited by 181
KRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 187
Pancreatic cancer: challenges and opportunities
Zhu, H., Li, T., Du, Y., & Li, M. (2018) · BMC Medicine · doi:10.1186/s12916-018-1215-3 · Cited by 187
The Pancreatic Cancer Microenvironment
Dougan, S. K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000288 · Cited by 187
Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O., Giryes, A., Decker, M., & Abdel-Rahman, O. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i10.1872 · Cited by 185
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy
Wang, L., Zhao, Z., Ozark, P. A., Fantini, D., Marshall, S. A., Rendleman, E. J., Cozzolino, K. A., Louis, N., He, X., Morgan, M. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0034-6 · Cited by 185
Papalazarou, V., Zhang, T., Paul, N. R., Juin, A., Cantini, M., Maddocks, O. D. K., Salmeron-Sanchez, M., & Machesky, L. M. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0159-z · Cited by 183
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Sodir, N. M., Kortlever, R. M., Barthet, V. J. A., Campos, T., Pellegrinet, L., Kupczak, S., Anastasiou, P., Swigart, L. B., Soucek, L., Arends, M. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0435 · Cited by 182
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
“Activating mutations in KRAS occur in up to 93% of PDAC, while the majority of KRAS wild-type (WT) cases bear alternative genetic alterations predicted to result in ectopic RAS–ERK pathway activity, implying a critical requirement for this pathway in PDAC (3, 4).”
BackgroundMethodSelf-citationVallejo, A., Perurena, N., Guruceaga, E., Mazur, P. K., Martinez-Canarias, S., Zandueta, C., Valencia, K., Arricibita, A., Gwinn, D., Sayles, L. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14294 · Cited by 181
Self-citationLack of immunoediting in murine pancreatic cancer reversed with neoantigen
Evans, R. A., Diamond, M. S., Rech, A. J., Chao, T., Richardson, M. W., Lin, J. H., Bajor, D. L., Byrne, K. T., Stanger, B. Z., Riley, J. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88328 · Cited by 180
“In KPC mice, antitumor T cell immunity is barely measurable (17) and effector T cell infiltration into tumors is minimal at even the earliest stage of neoplasia (12, 13, 18) — similar to the dearth of T cells observed histologically in other oncogene-driven cancer GEMMs (19, 20) and in the majority of human PDA (21).”
BackgroundLesch, S., Blumenberg, V., Stoiber, S., Gottschlich, A., Ogonek, J., Cadilha, B. L., Dantes, Z., Rataj, F., Dorman, K., Lutz, J., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00737-6 · Cited by 178
Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
“Signatures enriched in immunogenic subtype might represent predictive biomarkers for immunotherapeutic response in PDAC (130).”
BackgroundCancer Cell–Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma
Tian, C., Öhlund, D., Rickelt, S., Lidström, T., Huang, Y., Hao, L., Zhao, R. T., Franklin, O., Bhatia, S. N., Tuveson, D. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2578 · Cited by 177
“Survival analysis Gene expression and clinical data for human pancreatic ductal adenocarcinoma (TCGA) were downloaded from cBioPortal (19).”
Ding, Y., Cao, F., Sun, H., Wang, Y., Liu, S., Wu, Y., Cui, Q., Mei, W., & Li, F. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.039 · Cited by 177
Singhi, A. D., Nikiforova, M. N., Chennat, J., Papachristou, G. I., Khalid, A., Rabinovitz, M., Das, R., Sarkaria, S., Ayasso, M. S., Wald, A. I., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317817 · Cited by 176
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
Guler, G. D., Ning, Y., Ku, C.-J., Phillips, T., McCarthy, E., Ellison, C. K., Bergamaschi, A., Collin, F., Lloyd, P., Scott, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18965-w · Cited by 177
De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0683-3 · Cited by 175
Self-citationTargeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer
Masoud, R., Reyes-Castellanos, G., Lac, S., Garcia, J., Dou, S., Shintu, L., Abdel Hadi, N., Gicquel, T., El Kaoutari, A., Diémé, B., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100143 · Cited by 175
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.